[10]
Richard, J., specifically noted that this statement did not provide a detailed statement of the legal and factual basis for the allegation as required by the
Regulations
. However, as in that matter, Novopharm had provided extensive information regarding the process, the court was able to dispose of the matter on the evidence. Richard, J., stated, at p. 420 [S.C.R.]:
"Because both parties have provided the court with ample evidence regarding the chemical composition of the drug and the processes involved in producing the product, I have not been required to base my determination on the operation of a legal burden of proof or a statutory or common law presumption, but on the construction of the patent at issue and the weighing of the considerable evidence adduced."